Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up

Next Previous
Search
Trial Profile

Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Risperidone (Primary) ; Clonazepam; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PAFIP3_1Y; PAFIP3_3Y

Most Recent Events

  • 11 Feb 2020 Planned End Date changed from 1 Jun 2021 to 1 Dec 2020.
  • 11 Feb 2020 Planned End Date changed from 1 Jun 2021 to 1 Dec 2020.
  • 22 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top